• Botanix agrees to terms with Piramal for manufacturing and supply of Sofpironium Bromide API
• Alternate API supplier to de-risk supply chain and provide 25-40% reduction in cost of goods sold
• Establishment of second API supplier expected to increase gross profit

Botanix Pharmaceuticals Limited has announced that it has agreed to terms with PPL Pharma Solutions Riverview LLC ('Piramal') for a proposed manufacturing and supply arrangement. Under the term sheet, Piramal will commence certain development services and serve as an alternate commercial supplier of Sofpironium Bromide, the active pharmaceutical ingredient (API) in Botanix's FDA-approved product Sofdra. The technical transfer will commence immediately, and the parties will negotiate a definitive commercial API supply agreement. Establishment of an alternate API supplier for Sofdra will de-risk the Botanix supply chain and is anticipated to provide a potential 25% - 40% reduction in cost of goods sold and increase gross profit. Botanix is a commercial dermatology company based in Philadelphia and Phoenix, US, that has received FDA approval for Sofdra, its product for the treatment of primary axillary hyperhidrosis.

Establishment of an alternate API supplier for Sofdra is anticipated to provide a potential 25% - 40% reduction in cost of goods sold and increase gross profit.